Sponsor content
November 2016

Taking RNAi under the skin

The potential of gene silencing via RNAi has long been recognized, and innovations in the delivery of RNAi therapeutics by Dicerna Pharmaceuticals have enabled potent, long-acting gene silencing with a single subcutaneous injection for liver-associated diseases.

Thumb icon1
Dicerna Pharmaceuticals
Oct 25, 2016
2
0
Like 2 Comment
Page of
Previous

Voyager Therapeutics Profile November 2016
Back to November 2016
Next

Astex targets CNS with fragment-based approach
Medium icon1

Dicerna Pharmaceuticals

Dicerna is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for other therapeutic areas in which the liver plays a key role.

No comments yet.